Loading clinical trials...

Auto Stem Cell Transplant for Lymphoma Patients | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Auto Stem Cell Transplant for Lymphoma Patients

Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

NCT03125642•Masonic Cancer Center, University of Minnesota

Summary

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

Eligibility

Age

0 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Eligible Diseases
•1. Non-Hodgkin's Lymphoma (NHL)
•* Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.
•* Patients in partial or complete remission following cell therapy will also be eligible.
•* NHL patients with resistant or refractory lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial.
•* Lymphoblastic Lymphoma:
•1. All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR)
•2. Patients with any high-risk features will be eligible in first complete remission
•3. High risk features include: Stage IV, LDH \>2 x upper limit of normal, ≥ 2 extranodal sites
•* Mature B-cell Lymphoma
+37 more criteria

Exclusion Criteria

•Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
•Eligible for any higher priority transplant protocols
•Chemotherapy resistant disease
•Unrelated active infection

Locations (1)

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States

Key Dates

Start Date

April 20, 2017

Primary Completion Date

September 30, 2026

Completion Date

April 30, 2027

Last Updated

November 4, 2025

Enrollment

150

ESTIMATED participants

Conditions

Non-Hodgkin LymphomaHodgkin Lymphoma

Interventions

Etoposide

DRUG

BCNU

DRUG

AraC

DRUG

Melphalan

DRUG

Peripheral blood stem cell transplantation

PROCEDURE

G-CSF

BIOLOGICAL

Cyclophosphamide

DRUG

Total Body Irradiation

RADIATION

Contacts

Timothy Krepski

CONTACT

612-273-2800 tkrepsk1@fairview.org

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Auto Stem Cell Transplant for Lymphoma Patients

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma